Bender Robert & Associates Invests $277,000 in Evolus, Inc. (NASDAQ:EOLS)

Bender Robert & Associates purchased a new stake in Evolus, Inc. (NASDAQ:EOLS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 25,070 shares of the company’s stock, valued at approximately $277,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Barclays PLC boosted its holdings in Evolus by 268.0% in the third quarter. Barclays PLC now owns 93,662 shares of the company’s stock valued at $1,518,000 after purchasing an additional 68,213 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Evolus by 173.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after purchasing an additional 265,635 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Evolus by 9.8% in the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company’s stock valued at $368,000 after purchasing an additional 2,989 shares during the period. Jane Street Group LLC grew its stake in Evolus by 47.0% during the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock worth $1,489,000 after buying an additional 29,396 shares during the last quarter. Finally, Lord Abbett & CO. LLC increased its position in Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock worth $16,126,000 after buying an additional 188,685 shares during the period. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Stock Performance

Shares of EOLS stock opened at $12.71 on Wednesday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a 50 day simple moving average of $12.98 and a 200-day simple moving average of $14.03. The company has a market cap of $808.19 million, a price-to-earnings ratio of -13.97 and a beta of 1.28. Evolus, Inc. has a 12-month low of $9.25 and a 12-month high of $17.82.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Evolus in a report on Wednesday, March 5th. Finally, Barclays increased their price objective on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.